201 results about "Coliform bacilli" patented technology

The invention discloses a method for preparing a nanofibre membrane, belonging to a technique for preparing a nanofibre compound membrane. The method comprises the following steps: preparing curcuminethanol solution and chitosan acetum, mixing the curcumin ethanol solution and the chitosan acetum by the volume ratio thereof to prepare spinning solution which is injected into an injector of an electrostatic spinning device for electrostatic spinning to form a compound nanofibre membrane and to obtain a curcumin/chitosan nanofibre membrane of antibacterial property, wherein the diameter of thecurcumin/chitosan nanofibre membrane is 200-400 nm. The invention has the advantages that the preparation process is simple, the prepared membrane material heals wound, has broad spectrum bactericidalproperty and has higher bacterial inhibition rate to colibacillus and staphylococcus aureus for 24h.

The invention provides a preparation method of 3'-sialic acid lactose, belonging to the technical field of biological engineering. The preparation method comprises the following steps of: taking colibacillus CCTCC (colibacillus China center for type culture collection) NO: M208088 as a starting strain, adding a fermentation medium into a fermentation tank, fermenting for 2-6h, then adding a fed batch culture medium, and adding lactose in a flowing way at the mid-later period of the fermentation; and centrifuging the fermentation liquid to obtain liquid supernatant 1 and a thallus, diluting the centrifuged thallus by adding water and splitting in a heating way, recentrifuging to obtain liquid supernatant 2, merging the liquid supernatant 1 and the liquid supernatant 2, and absorbing, desorbing and vacuum drying by ion exchange resin to obtain the 3'-sialic acid lactose. A mass of the 3'-sialic acid lactose can be prepared by the CCTCC NO: M208088. The 3'-sialic acid lactose can change the current situation that the sialyloligosaccharide component is less in exogenous adding substances in conventional baby milk, and can provide the guarantee to add more efficient sialic acid trophic factors into the baby milk.

This invention relates to a fusion protein used for preventing aftosa, its preparation method and application. This fusion protein contains O type foot-and-mouth disease virus main cytomembrane protein VP1 epitope, colibacillus thermolability toxin B subunit, thymus derived cell epitope and purification label.

The invention relates to the field of feed, in particular to a compound premix feed of 1% green laying hens in laying period. The compound premix feed of 1% green laying hens in laying period is formed by uniformly mixing micronutrient substances of trace elements, vitamins, synthetic amino acids and the like, feed additives and powdered grain feed as a carrier, and is characterized by comprising active dry yeast, lactic acid bacteria, bacillus and digestive ferment. In the compound premix feed of 1% green laying hens in laying period, active dry yeast, growing element for poultry containing lactic acid bacteria and bacillus can inhibit propagation of pathogen; in wet mixed feed, active dry yeast and the like can be propagated and fermented, and partial pathogen can be inhibited and killed; and the palatability and digestibility of the feed can be improved in a certain time range. Microzyme, lactic acid bacteria and bacillus enter an alimentary tract for quick propagation, and can inhibit the growth of pathogen such as colon bacillus, salmonella and the like, thereby reducing diseases caused by pathogen, generating the effect similar to antibiotics, eliminating the damage of antibiotics to enteric microorganisms, better balancing intestinal flora, improving the immunizing power of laying hens, and improving the health level of laying hens.

The invention provides a SOD gene from animal and a method for cloning and expressing the SOD gene in colibacillus and yeast cells, wherein a nucleotide sequence of superoxide dismutase is shown as SEQ NO.1; an amino acid sequence of the superoxide dismutase is shown as SEQ NO.2; carriers of nucleotide molecules are colibacillus plasmids or yeast plasmids; cells of the nucleotide molecules are formed by carrier conversion; and cells of the nucleotide molecules of the superoxide dismutase contain colibacillus containing the nucleotide molecules or converted by the carriers or pichia yeast containing the nucleotide molecules or converted by the carriers. The invention can prepare recombinant production strains which can efficiently express and secrete Cu/Zn-SOD, realizes the production industrialization of the Cu/Zn-SOD, and achieves good pH stability, favorable thermal stability and Cu/Zn-SOD products with anti-protease hydrolyzation capacity.

The present invention relates to pig reproduction and respiratory syndrome virus recombined adenovirus and vaccine, and belongs to the field of biological high-tech. Through RT-PCR process to proliferate whole PRRSV GP5 sequence, cloning the gene sequence to the shuttle vector pShuttle-CMV of adenovirus carrier system, cotransforming colibacillus BJ5183 strain together with the skeleton vector of adenovirus carrier system to obtain recombinant plasmid, transfecting HEK293-A cell to obtain recombinant adenovirus and plaque purification, and RT-PCR and indirect immunofluorescence technique inspection, the recombinant adenovirus rAd-GP5 expressing PRRSV GP5 protein is constituted. The recombinant adenovirus can set ahead the expression of PRRSV GP5 protein and raise the expression amount to simulate the immune protecting reaction of body effectively.

A fire-resistant and acid-proof alpha-amylase and its production are disclosed. The process is carried out by separating precursor-alpha-amylase gene from lichenized bacillosporin, mutating for L134 and S320 amino acid residues and high-efficient expressing alpha-amylase mutant in bacterium. It achieves better safety, expression and acid stability, and more yield.

The invention relates to the field of pharmaceutical preparations and particularly relates to a slow-release micropill preparation containing enrofloxacin and a preparation method of the preparation. The slow-release micropill provided by the invention is formed by coating an enrofloxacin micropill; the enrofloxacin micropill comprises enrofloxacin and auxiliary material and is formed through extruding and rounding; the auxiliary material is any one or more of microcrystalline cellulose, starch, cane sugar, artificial gum, lactose and sodium carboxymethyl starch; according to weight percent, the auxiliary material in the micropill accounts for 70% to 95%; and coating is made of high-molecular enteric material, film forming material, opaquer and the like. The slow-release micropill preparation has the characteristics of slow release and high bioavailability, can be used for treating bacteria and mycoplasma infection of livestocks, and has better curative effect on chronic respiratory diseases, colibacillosis and salmonellosis, and the frequency of medicine taking can be reduced; and in addition, the slow-release micropill provided by the invention has the advantages that the stability of medicine is improved, and peculiar bitter of enrofloxacin can be covered completely, so that feeding intake of the animals is not influenced, and the recovery rate is improved.

This invention relates to one kind of the antibacterial hydroxyl apatite compound coat, the preparation method and the application, its characteristic is the related compound coat is composed of the metal silver powder and the hydroxyl apatite powder, the metal silver powder is treated as the antibacterial increase ingredient, the silver powder' quality accounts for 1-5% of the compound coat, the particle size of the silver powder is 20-100mum, the particle size of the hydroxyl apatite powder is 10-100mum. This invention making the compound coat is realized by using the spray technics of the vacuum plasma. The provided compound coat has an above 95% excellent antibacterial effect on the coliform, the green pus pseudomonad and the golden yellow staphylococcus, and the cytotoxic rank in vitro of the compound coat is zero, has no cytotoxicity.

The invention relates to a lactobacillus and in particular relates to a low-temperature resistant lactobacillus with ACE (angiotensin converting enzyme) inhibitory activity. The low-temperature resistant lactobacillus with the ACE inhibitory activity is lactobacillus plantarum I1 which is preserved in the China general microbiological culture collection center of which the preservation address is No.3, No1. yard, Beichen west road, Chaoyang District of Beijing, the preservation data is September 18th, 2012, and the preservation number is CGMCC No.6575; the lactobacillus plantarum I1 has the ACE inhibitory rate being 66%, can tolerate 6% of NaCl and 100mg/kg of nitrite, and can fast generate acid; the growing temperature of the lactobacillus plantarum I1 is 4-40 DEG C, and is suitable for low-temperature fermentation; and the low-temperature resistant lactobacillus has obvious protease activity and lipase activity, can not generate mucus, has an obvious antibacterial effect on staphylococcus aureus and colon bacillus, and can be used as a meat product leavening agent strain under a low-temperature condition.

An efficient angiogenesis depressant HM-3 for treating the solid tumors including stomach cancer, lung cancer and liver cancer is prepared through expressing in colibacillus by genetic engineering method, separating the protein of inclusion body, dissolving, re-naturalizing, and separating-purifying by ion change and chromatography.

Said invention relates to a nano antibiotic intelligent heat storage fiber and preparation and use thereof, which is composed of polypropylene, polyester, polyamide, polycarylonitrile and viscose fiber wherein the nano antibiotic intelligent heat storage function powder of 0.5-4 % of total fiber weight is uniformly distributed in fiber and surface layer. Said invention can absorb visible light source and convert into heat energy, also can absorb human body heat and store in fiber fabric then warm human body. Said invention has bacteriostasis and antibiotic effect to colibacillus, candida albicans, staphylococcus, gonorrhea, hepatitis etc.

The invented beta-gelase gene agaA is the gene of beta-gelase of coded pseudoallomonad CY24, the recombinant beta-glase produced by using it has good temp. and pH stability, high activity, can degrade agarose, and its degraded product mainly is new agar oligose whose degree of polymerization is 2-6, so that it can be used for preparing new agar aligose and recovering DNA from agarose gel. The recombinant beta-gelase expressed by said invented colibacillus recombinant strain pEAG/BL 21 is 24% of total protein. Its expression level is high. It is easy to purity. After continuous passage of 20 generations its expression amount is not reduced, therefore said invention can be used for large scale production of recombinant beta-gelase.

A composite Chinese veterinary medicine for preventing and treating the dysentery of piglet and the colibacillosis of fowls is prepared from 8 Chinese-medicinal materials including scutellaria root, cherokee rose-hip, sanguisorba root, lucid ligustrum fruit, etc through extracting in water, decocting twice, adsorbing and drying.

The invention discloses fusion protein with anti-tumor, anti-inflammation and oculopathy-treatment functions and a preparation method and application thereof, which belong to the technical field of biological pharmacy. Specifically, the invention relates to the fusion protein of an integrin blocking agent, which has the function of inhibiting tumor angiogenesis and has the integrin affinity and the combining capacity. A rigid (R) or flexible (F) linker is adopted to fuse two polypeptides, so as to respectively obtain protein A and protein G, the medicine effect can be increased, the half-life period can be extended, the stability can be enhanced, and the fusion protein has the characteristics of strong action effect, low toxicity and the like and can be used for preventing and treating solid tumors, all kinds of inflammation and angiogenesis oculopathy. The fusion protein structurally comprises two angiogenesis inhibiting polypeptides and the amino acid linker between the two angiogenesis inhibiting polypeptides, and the fusion protein is expressed in colibacillus or eukaryocyte by using a genetic engineering method and is obtained through separation and purification of a GST (Glutathione S Transferase) affinity column.

The invention relates to a method for screening single chain antibodies of Microcystin-LR and verification thereof. The method comprises the following steps: carrying out two rounds of affinity screening on the biotinylated Microcystin-LR in a human source synthetic antibody library by using an avidin labeled magnetic bead and a negative screening method; extracting total plasmid DNA from phage colonies produced in the second round, carrying out enzyme digestion with enzyme Sfi I, recycling gel to obtain single chain antibody genes, connecting the single chain antibody genes with soluble expression carrier pAK100CL which is processed by enzyme digestion in the same way, and electrically transforming the connected carrier into colibacillus XL1-Blue to obtain soluble expression single chain antibodies; and verifying the soluble expression single chain antibodies by using a competitive time-resolved fluorescence immune analytical method. The invention has the advantage of quick, simple and convenient screening, and can well expose the Microcystin-LR three-dimensional structure into the incubation system. The verification on the screening result has the advantages of high detection signal and strong anti-interference capacity against stroma.

The present invention relates to a beta-gelase gene agaB. It is a gene of beta-gelase of coded pseudoallomonad CY24. Said beta-gelase coded by beta-gelase gene agaB can specifically degrade agar to produce new agar oligose whose degree of polymerization is 8-14, said new agar oligose content content in the degraded product is greater than 20%. The recombinant beta-glase expressed by colibacillus recombinant strain BL21-pET24-agaB is 25% of total protein, its expressing level is high, and its purification is easy, so that it can be used for large-scale production of beta-gelase.

The invention discloses protein ompK subunit vaccine of assistant haemolysis vibrio extine and a preparation method thereof. The vaccine is PBS solution which converts the recombination protein of the coliform bacteria of recombination prokaryon expression plasmid pET30a-ompK expressed by inducing and after being purified; the concentration of the PBS solution is 0.25-0.5mg/ml. The method has the steps that: firstly, the extraction of an assistant haemolysis vibrio full gene group, the overall length of extine protein ompK DNA and the clone of a mature peptide coded sequence; secondly, the construction of a prokaryon expression plasmid of the ompK mature peptide coded sequence, thirdly, the obtaining way of the recombination ompK protein; fourthly, the detection to the immunity way and the immunity effect of a large yellow croaker with recombination ompK protein. The invention provides the preparation method of the assistant haemolysis vibrio ompK protein subunit vaccine, and simultaneously provides the detection method of the immunity effect of the large yellow croaker with recombination ompK protein, the preparation method is simple, and the usage is convenient.

The invention discloses a leifsonia xyli HSO904-based short chain dehydrogenase, and an encoding gene, a carrier, engineering bacteria and application thereof. A gene of the leifsonia xyli HSO904-based short chain dehydrogenase has more than 90% of homology of a nucleotide sequence shown in SEQ ID NO. 1. A colon bacillus BL21/pET28a (+)-SDR prepared by the recombination of the short chain dehydrogenase is used as an enzyme source, 3, 5-bis-trifluoro methyl acetophenone, trifluoromethyl acetophenone, 4-hydroxyl-2-butanone, acetoacetic ester, 4-chloro ethyl acetoacetate, acetoacetic acid tert-butyl acetate and the like are used as substrates to prepare corresponding chiral compounds such as (R)-3, 5-bis-trifluoromethyl phenethyl alcohol, trifluoromethyl benzaldehyde ethanol, 2-hydroxyl-butyl alcohol, 3-hydroxy ethyl butyrate, 4-chloro-3-hydroxy ethyl butyrate and 3-hydroxy butyric acid tert-butyl acetate through a catalytic asymmetric reduction reaction.

The invention discloses an antibiotic polylactic acid fiber and a preparation method thereof. The preparation method comprises the following steps: preparing a polylactic acid fiber through a chemical grafting technology, immersing the polylactic acid fiber in a degrading solution to carry out grading in order to obtain a polylactic acid fiber with the surface containing hydroxyl groups, immersing the polylactic acid fiber with the surface containing hydroxyl groups in an acetic acid solution, reacting to obtain a modified polylactic acid fiber with the surface containing bromo groups, adding dimethylaminoethyl methacrylate, a catalyst and a ligand to obtain a polylactic acid fiber with the surface grafted with polydimethylaminoethyl methacrylate, immersing the polylactic acid fiber with the surface grafted with polydimethylaminoethyl methacrylate in n-hexane, and processing to obtain the polylactic acid fiber with the surface containing an antibiotic quaternary ammonium salt. The preparation method is simple, and the surface of the fiber is grafted with the above antibiotic substance, so the antibiotic substance difficultly sheds, and fabrics have good washing durability; the antibiotic substance is not added in the processing process, so the flexibility of the polylactic acid fiber is not affected; and the antibacterial rate of the prepared polylactic acid fiber to Escherichia coli is 96.7% or above, and the antibacterial rate of the polylactic acid fiber to Staphylococcus aureus is 95%.

The invention provides injectable composite antibacterial hydrogel and a preparation method thereof. The method comprises the steps that in the presence of a catalyst, a carboxylated polyvinyl alcoholsolution undergoes a reaction with epsilon-polylysine after the pH value is adjusted to 3-4 so that an amino-modified polyvinyl alcohol solution is obtained, and a chitosan solution, an aldehyde dextran solution and the amino-modified polyvinyl alcohol solution are mixed to form the injectable composite antibacterial hydrogel, wherein the mass ratio of the amino-modified polyvinyl alcohol to thechitosan to the hydroformylation glucan is (4-1): 1: (0.05-0.5). According to the method, amino-modified polyvinyl alcohol with an antibacterial function is blended with chitosan, and then a dynamic Schiff base bond is constructed by utilizing amino groups on molecular chains of the polyvinyl alcohol and the chitosan and aldehyde groups on molecular chains of hydroformylation glucan, so that the hydrogel has reversible cross-linking property and is an intrinsic antibacterial material. The antibacterial rate is higher. The highest antibacterial rate of the hydrogel prepared by the embodiment ofthe invention on escherichia coli and staphylococcus aureus reaches 99.99%.